The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.

Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve a functional or complete cure. Capsid assembly modulators inhibit the ...

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – “We are pleased to highlight ...

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity ...

– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – SOUTH SAN ...

A study by chemists at the University of Chicago has uncovered a new key step in the process that HIV uses to replicate itself. The study, published Jan. 6 in Science Advances, used computer modeling ...

Researchers develop a large dodecahedral structure through the self- assembly of metal ions and peptides, with potential implications in drug delivery systems and molecular transportation. Controlling ...

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 ...

New hollow dodecahedral shell demonstrates remarkable stability and potential for functionalization and encapsulating macromolecules. (Nanowerk News) Controlling the topology and structure of ...

– In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment – – Enrollment in final cohort of 400 mg ...